The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease

Atherosclerosis

Volumn 152, Issue 2, 2000, Pages 421-431

  Gardemann, Andreas ^a   Philipp, Monika ^a   Heß, Kerstin ^a   Katz, Norbert ^a   Tillmanns, Harald ^a   Haberbosch, Werner ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Apolipoprotein AI; Coronary heart disease; Coronary risk factors; Gensini score; High density lipoprotein; Myocardial infarction

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN;

ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; GENETIC MARKER; GENOTYPE; HEART INFARCTION; HUMAN; HUMAN EXPERIMENT; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; ARYLDIALKYLPHOSPHATASE; CORONARY DISEASE; ESTERASES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0033811695     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00489-X     Document Type: Article

References (49)

1. Badimon J.J., Fuster V., Badimon L. Role of high density lipoproteins in the regression of atherosclerosis. Circulation. 86:(Suppl III):1992;86-94.
2. Tribble D.L., Kraus R.M. HDL and coronary artery disease. Adv. Intern. Med. 38:1993;1-39.
3. Parthasarathy S., Barnett J., Fong L.G. High density lipoprotein inhibits the oxidative modification of low density lipoprotein. Biochim. Biophys. Acta. 1044:1990;275-283.
4. Klimov A.N., Gurevich V.S., Nikiforova A.A., Shatilina L.V., Kuzmin A.A., Plavinsky S.L., Teryukova N.P. Antioxidative activity of high-density lipoprotein in vivo. Atherosclerosis. 100:1993;13-18.
5. Mackness M.I., Durrington P.N. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 115:1995;243-253.
6. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. New Engl. J. Med. 320:1999;915-924.
7. Berliner J.A., Navab M., Fogelman A.M., Frank J.S., Demer L.L., Edwards P.A., Watson A.D., Lusis A.J. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 91:1995;2488-2496.
8. Berliner J.A., Leitinger N., Watson A., Huber J., Fogelman A., Navab M. Oxidized lipids in atherogenesis: formation, destruction and action. Thromb. Haemost. 78:1997;195-199.
9. Aviram M., Fuhrman B. LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants. Mol. Cell. Biochem. 188:1998;149-159.
10. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidised low-density lipoprotein. J. Clin. Invest. 96:1995;2882-2891.
11. Aviram M. Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol. Med. Today. 5:1999;381-386.
12. Mackness M.I., Mackness B., Durrington P.N., Fogelman A.M., Berliner J., Lusis A.J., Navab M., Shih D., Fonarow G. Paraoxonase and coronary heart disease. Curr. Opin. Lipidol. 9:1998;319-324.
13. Shih D.M., Gu L.J., Xia Y.R., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394:1998;284-287.
14. McElveen J., Mackness M.I., Colley C.M., Peard T., Warner S., Walker C.H. Distribution of paraoxonase hydrolytic activity in the serum of patients after myocardial infarction. Clin. Chem. 32:1986;671-673.
15. Mackness M.I., Harty D., Bhatanagar D., Winocour P.H., Arrol S., Ishola M., Durrington P.N. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 86:1991;193-199.
16. Mackness M.I., Peuchant E., Dumon M.-F., Walker C.H., Clerc M. Absence of 'A'-esterase activity in patients with Tangier disease. Clin. Biochem. 22:1989;475-478.
17. Mackness M.I., Walker C.H., Carlson L.A. Low 'A'-esterase activity in serum of patients with fish-eye disease. Clin. Chem. 33:1987;587-588.
18. Mackness B., Hunt R., Durrington P.N., Mackness M.I. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler. Thrombosis Vasc. Biol. 17:1997;1233-1238.
19. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3:1993;73-76.
20. Ruiz J., Blanche H., James R.W., Blatter M.C., Charpentier G., Morabia A., Passa P., Froguel P. The polymorphism (Gln-Arg192) of the high-density lipoprotein-bound enzyme is an independent cardiovascular risk factor in non-insulin dependent diabetic patients. Lancet. 346:1995;869-872.
21. Odawara M., Tachi Y., Yamashita K. Paraoxonase polymorphism (Gln(192)-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:1997;2257-2260.
22. Pfohl M., Koch M., Enderle M.D., Kuhn R., Fullhase J., Karsch K.R., Haring H.U. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes. 48:1999;623-627.
23. Serrato N, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary heart disease, J Clin Invest 96:3005-3008.
24. Sanghera D.K., Saha N., Aston C.E., Kamboh M.I. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 17:1997;1067-1073.
25. Zama T., Murata M., Matsubara Y., Kawano K., Aoki N., Yoshino H., Watanabe G., Ishikawa K., Ikeda Y. A (192)Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler. Thromb. Vasc. Biol. 17:1997;3565-3569.
26. Suehiro T., Nakauchi Y., Yamamoto M., Arii K., Itoh H., Hamashige N., Hashimoto K. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int. J. Cardiol. 57:1996;69-73.
27. Sodeyama N., Yamada M., Itoh Y., Suematsu N., Matsushita M., Otomo E., Mizusawa H. No association of paraoxonase gene polymorphism with atherosclerosis or Alzheimer's disease. Neurology. 53:1999;1146-1148.
28. Antikainen M., Murtomäki S., Syvänne M., Pahlman R., Tahvanainen E., Jauhianen M., Frick M.H., Ehnholm C. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J. Clin. Invest. 98:1996;883-885.
29. Herrmann S.M., Blanc H., Poirier O., Arveiler D., Luc G., Evans A., Marques Vidal P., Bard J.M., Cambien F. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis. 126:1996;299-303.
30. Rice G.I., Ossei-Gerning N., Stickland M.H., Grant P.J. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease. Coronary Artery Dis. 8:1997;677-682.
31. Ko Y.L., Ko Y.S., Wang S.M., Hsu L.A., Chang C.J., Chu P.H., Cheng N.J., Chen W.J., Chiang C.W., Lee Y.S. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis. 141:1998;259-264.
32. Ombres D., Pannitteri G., Montali A., Candeloro A., Seccareccia F., Campagna F., Cantini R., Campa P.P., Ricci G., Arca M. The gln-arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler. Thromb. Vasc. Biol. 18:1998;1611-1618.
33. Hasselwander O., Savage D.A., McMaster D., Loughrey C.M., McNamee P.T., Middleton D., Nicholls D.P., Maxwell A.P., Young I.S. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int. 56:1999;289-298.
34. Blatter Garin M.C., James R.W., Dussoix P., Blanche H., Passa P., Froguel P., Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. J. Clin. Invest. 99:1997;62-66.
35. Malin R., Huang X.H., Wirta O., Rantalaiho V., Pasternack A., Jokela H., Koivula T., Lehtimaki T. The Met54Leu polymorphism of paraoxonase (PON) enzyme gene is not a genetic risk factor for non-insulin-dependent diabetes mellitus in Finns. Clin. Genet. 54:1998;254-255.
36. Sanghera D.K., Saha N., Kamboh M.I. The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis. 136:1998;217-223.
37. Gensini G.G. A more meaningful scoring system for determining the severity of coronary heart disease. Am. J. Cardiol. 51:1983;606.
38. Rose D.A. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull. World Health Organisation. 27:1962;645-648.
39. Gardemann A., Fink M., Stricker J., Nguyen Q.D., Humme J., Katz N., Tillmanns H., Hehrlein F.W., Rau M., Haberbosch W. ACE I/D gene polymorphism: presence of the ACE D allele increases the risk of coronary artery disease in younger individuals. Atherosclerosis. 139:1998;153-159.
40. Gardemann A., Humme J., Stricker J., Nguyen Q.D., Katz N., Philipp M., Tillmanns H., Hehrlein F.W., Rau M., Haberbosch W. Association of the platelet glycoprotein IIIa PIA1/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thrombosis Haemostasis. 80:1998;214-217.
41. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions - A possible peroxidative role for paraoxonase. J. Clin. Invest. 101:1998;1581-1590.
42. Adkins S.K.N., Gan N., Mody M., La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B alloenzymes. Am. J. Hum. Genet. 52:1993;598-608.
43. Nevin D.N., Zambon A., Furlong C.E., Richter R.J., Humbert R., Hokanson J.E., Brunzell J.D. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arteroscler. Thromb. Vasc. Biol. 16:1996;1243-1249.
44. Cao H.B., Girard-Globa A., Berthezene F., Moulin P. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism. J. Lipid Res. 40:1999;133-139.
45. Mackness B., Mackness M.I., Arrol S., Turkie W., Durrington P.N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 423:1998;57-60.
46. Mackness B., Durrington P.N., Mackness M.I. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet. 353:1999;468-469.
47. Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., Erogul J., Hsu C., Dunlop C., La Du B. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities - selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18:1998;1617-1624.
48. Lansbury A.J., Catto A.J., Carter A.M., Bamford J.M., Grant P.J. The paraoxonase glutamine/arginine polymorphism and cerebrovascular disease. Cerebrovasc. Dis. 7:1997;353-355.
49. Cao H.B., Girard-Globa A., Serusclat A., Bernard S., Bondon P., Picard S., Berthezene F., Moulin P. Lack of association between carotid intima-media thickness and paraoxonase gene polymorphism in non-insulin dependent diabetes mellitus. Atherosclerosis. 138:1998;361-366.